This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Innovent’s record-breaking US$11.4 billion BsAb and ADC partnership with Takeda, DualityBio’s plans for a STAR Market IPO after positive HER2 ADC Phase III data, Biokin’s US$250 million milestone payment from BMS and HKEX IPO approval, and Haixi Pharma’s 36% intraday surge on its HKEX debut. Key clinical updates from ESMO 2025 include Akeso’s ivonescimab outperforming PD-1 combos in NSCLC, RemeGen’s breakthrough urothelial carcinoma ADC data, and CARsgen’s promising pancreatic cancer CAR-T results. Additional developments include Starna Therapeutics’ RMB 300 million Series B funding for in vivo CAR-T, and Jiangsu Hengrui’s significant oncology progress across KRAS-mutated tumors, HCC, and breast cancer.
